Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05185570
Other study ID # Soh-Med-21-12-01
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date January 2022
Est. completion date October 2022

Study information

Verified date December 2021
Source Sohag University
Contact Abeer H Mohammed
Phone 01019585267
Email abeer011116@med.sohag.edu.eg
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Acute poisoning is a major public health problem all over the world, it causes significant mortality and morbidity. It primarily involves younger populations, with less than 3% of the affected cases being in people aged 60 years or older in most studies. More than half of the intoxication events in the elderly over 65 years old were accidental.


Description:

The elderly are different from younger adults in many aspects. There are age related physiological changes. They have a higher incidence of comorbidities and use of many medications for chronic conditions, both of which make the elderly more susceptible to acute poisoning and its related consequences. Although the elderly form a relatively small proportion of those admitted to hospital for acute self-poisoning, the poisoning in them is often more serious, complications are more frequent and a fatal outcome is more common. The presence of multiple physical, social, and psychiatric problems, with possible difficulties in the diagnosis of poisoning make the management of the elderly more complicated than that of younger poisoned patients. There are three main difficulties in diagnosing acute poisoning in the elderly. At first, it may not be easily obvious that the patient has taken an overdose. Secondly, the presence of pre-existing diseases may obscure the clinical picture and finally, the drug may cause physical signs that similar to common problems of old age.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 20
Est. completion date October 2022
Est. primary completion date June 2022
Accepts healthy volunteers No
Gender All
Age group 60 Years and older
Eligibility Inclusion Criteria: all patients more than 60 years will be included. Exclusion Criteria: younger than 60 years.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Sohag University

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Acute physiology and chronic health evaluation II score (APACHE II) in cases of elderly patients with acute poisoning. "Acute Physiology And Chronic Health Evaluation II(APACHE II) " is a severity-of-disease classification system. one of several ICU scoring systems. It is applied within 24 hours of admission of a patient to an intensive care unit (ICU): an integer score from 0 to 71 is computed based on several measurements; higher scores correspond to more severe disease and a higher risk of death. 24 hours after admission to intensive care unit (ICU).
Primary Change in Poisoning Severity Score (PSS) in cases of elderly patients with acute poisoning. "Poisoning Severity Score (PSS)" is a standardized scale for grading the severity of poisoning allows qualitative evaluation of. morbidity caused by poisoning, better identification of real risks and comparability of data. 24 hours after admission to intensive care unit (ICU).
See also
  Status Clinical Trial Phase
Completed NCT00780078 - Clinical Evaluation of Swallowing Disorders as a Predictor of Extubation Failure N/A
Not yet recruiting NCT05148611 - Application Registration Study of ILE in Patients With Acute Poisoning
Recruiting NCT06447584 - Clinical Spectrum and Outcome of Poisoning in Children Admitted to the Pediatric Emergency and Intensive Care Units at Sohag University Hospital
Completed NCT06316362 - Efficacy of SMOF Lipid in the Management of Acute Poisoning With Carbamazepine Phase 2
Completed NCT06413589 - Efficacy of SMOF Lipid in the Management of Acute Poisoning With Clozapine Phase 2